110 related articles for article (PubMed ID: 12890147)
41. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
42. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer.
Grignon DJ; Sakr W; Toth M; Ravery V; Angulo J; Shamsa F; Pontes JE; Crissman JC; Fridman R
Cancer Res; 1996 Apr; 56(7):1654-9. PubMed ID: 8603416
[TBL] [Abstract][Full Text] [Related]
43. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
44. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
45. The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis.
Kelly BC; Markle LS; Vickers JL; Petitt MS; Raimer SS; McNeese C
J Am Acad Dermatol; 2010 Sep; 63(3):483-9. PubMed ID: 20708474
[TBL] [Abstract][Full Text] [Related]
46. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis.
Sanders JS; van Goor H; Hanemaaijer R; Kallenberg CG; Stegeman CA
Nephrol Dial Transplant; 2004 Jun; 19(6):1412-9. PubMed ID: 15034162
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma.
Hazar B; Polat G; Seyrek E; Bağdatoğlğlu O; Kanik A; Tiftik N
Int J Clin Pract; 2004 Feb; 58(2):139-43. PubMed ID: 15055861
[TBL] [Abstract][Full Text] [Related]
48. Non-Hodgkin's lymphomas: immunologic prognostic studies.
Hadzi-Pecova L; Petrusevska G; Stojanovic A
Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
[TBL] [Abstract][Full Text] [Related]
49. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
50. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
Thomas CV; Coker ML; Zellner JL; Handy JR; Crumbley AJ; Spinale FG
Circulation; 1998 May; 97(17):1708-15. PubMed ID: 9591765
[TBL] [Abstract][Full Text] [Related]
51. Matrix metalloproteinase-2 promoter and tissue inhibitor of metalloproteinase-2 gene polymorphisms in non-Hodgkin's lymphoma.
Diao LP; Ma H; Wei GC; Li T; Liu HS; Liu LH; Wu LL; Zhao GM; Gao YH
Int J Cancer; 2012 Sep; 131(5):1095-103. PubMed ID: 22020421
[TBL] [Abstract][Full Text] [Related]
52. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis.
Naito K; Takahashi M; Kushida K; Suzuki M; Ohishi T; Miura M; Inoue T; Nagano A
Rheumatology (Oxford); 1999 Jun; 38(6):510-5. PubMed ID: 10402070
[TBL] [Abstract][Full Text] [Related]
53. Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial adenocarcinoma.
Laird SM; Dalton CF; Okon MA; Bunning RA; Marshall R; Li TC
J Reprod Fertil; 1999 Mar; 115(2):225-32. PubMed ID: 10434927
[TBL] [Abstract][Full Text] [Related]
54. Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia.
Lin LI; Lin DT; Chang CJ; Lee CY; Tang JL; Tien HF
Br J Haematol; 2002 Jun; 117(4):835-41. PubMed ID: 12060118
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer.
Sharma R; Chattopadhyay TK; Mathur M; Ralhan R
Oncology; 2004; 67(3-4):300-9. PubMed ID: 15557792
[TBL] [Abstract][Full Text] [Related]
56. Role of matrix metalloproteinase (MMP) 2 and MMP-9 in soft tissue sarcoma.
Yang HK; Jeong KC; Kim YK; Jung ST
Clin Orthop Surg; 2014 Dec; 6(4):443-54. PubMed ID: 25436070
[TBL] [Abstract][Full Text] [Related]
57. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis.
de Vicente JC; Lequerica-Fernández P; Santamaría J; Fresno MF
J Oral Pathol Med; 2007 Aug; 36(7):415-24. PubMed ID: 17617835
[TBL] [Abstract][Full Text] [Related]
58. A study of metalloproteinases in fifty joint fluid specimens.
Gaudin P; Razakaboay M; Surla A; Berthier S; Fauconnier J; Morel F; Phelip X
Rev Rhum Engl Ed; 1997 Jun; 64(6):375-81. PubMed ID: 9513609
[TBL] [Abstract][Full Text] [Related]
59. Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease.
Ekekezie II; Thibeault DW; Simon SD; Norberg M; Merrill JD; Ballard RA; Ballard PL; Truog WE
Pediatrics; 2004 Jun; 113(6):1709-14. PubMed ID: 15173495
[TBL] [Abstract][Full Text] [Related]
60. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
